Exagen Inc.
Exagen Inc. (XGN) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Exagen Inc. (XGN), featuring income statements, balance sheets, and cash flow data.
Exagen Inc. (XGN) Income Statement & Financial Overview
View the income breakdown for Exagen Inc. XGN across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $15.50M | $13.65M | $12.51M | $15.06M |
| Cost of Revenue | $6.38M | $5.18M | $5.53M | $6.008M |
| Gross Profit | $9.12M | $8.48M | $6.98M | $9.06M |
| Gross Profit Ratio | $0.59 | $0.62 | $0.56 | $0.60 |
| R&D Expenses | $1.28M | $1.66M | $1.48M | $1.18M |
| SG&A Expenses | $11.20M | $10.20M | $10.16M | $10.46M |
| Operating Expenses | $12.49M | $11.86M | $11.64M | $11.64M |
| Total Costs & Expenses | $18.86M | $17.04M | $17.17M | $17.65M |
| Interest Income | $158000.00 | $197000.00 | $197000.00 | $181000.00 |
| Interest Expense | -$545000.00 | $563000.00 | $562000.00 | $560000.00 |
| Depreciation & Amortization | $0.00 | $415000.00 | $422000.00 | $429000.00 |
| EBITDA | -$3.37M | -$2.77M | -$4.04M | -$1.98M |
| EBITDA Ratio | -$0.22 | -$0.20 | -$0.32 | -$0.13 |
| Operating Income | -$3.37M | -$3.38M | -$4.66M | -$2.59M |
| Operating Income Ratio | -$0.22 | -$0.25 | -$0.37 | -$0.17 |
| Other Income/Expenses (Net) | -$387000.00 | -$366000.00 | -$365000.00 | -$379000.00 |
| Income Before Tax | -$3.75M | -$3.75M | -$5.03M | -$2.97M |
| Income Before Tax Ratio | -$0.24 | -$0.27 | -$0.40 | -$0.20 |
| Income Tax Expense | $0.00 | $12000.00 | $0.00 | $0.00 |
| Net Income | -$3.75M | -$3.76M | -$5.03M | -$2.97M |
| Net Income Ratio | -$0.24 | -$0.28 | -$0.40 | -$0.20 |
| EPS | -$0.20 | -$0.20 | -$0.28 | -$0.16 |
| Diluted EPS | -$0.20 | -$0.20 | -$0.28 | -$0.16 |
| Weighted Avg Shares Outstanding | $18.56M | $18.20M | $18.25M | $18.18M |
| Weighted Avg Shares Outstanding (Diluted) | $18.56M | $18.20M | $18.25M | $18.18M |
The company's financials show resilient growth, with revenue advancing from $15.06M in Q2 2024 to $15.50M in Q1 2025. Gross profit remained healthy with margins at 59% in Q1 2025 compared to 60% in Q2 2024. Operating income hit -$3.37M last quarter, sustaining a consistent -22% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$3.37M. Net income rose to -$3.75M, while earnings per share reached -$0.20. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan